Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1981 1
1995 1
1997 1
2005 5
2006 3
2007 4
2008 6
2009 8
2010 10
2011 13
2012 16
2013 20
2014 13
2015 15
2016 24
2017 20
2018 26
2019 24
2020 10
2021 17
2022 17
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23149623

224 results

Results by year

Filters applied: . Clear all
Page 1
Improved glycemic control in mice lacking Sglt1 and Sglt2.
Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B. Powell DR, et al. Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E117-30. doi: 10.1152/ajpendo.00439.2012. Epub 2012 Nov 13. Am J Physiol Endocrinol Metab. 2013. PMID: 23149623 Free article.
Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A. Zambrowicz B, et al. Clin Ther. 2013 Aug;35(8):1162-1173.e8. doi: 10.1016/j.clinthera.2013.06.011. Epub 2013 Jul 31. Clin Ther. 2013. PMID: 23911260 Clinical Trial.
Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM. Powell DR, et al. J Pharmacol Exp Ther. 2014 Aug;350(2):232-42. doi: 10.1124/jpet.114.214304. Epub 2014 May 21. J Pharmacol Exp Ther. 2014. PMID: 24849925
Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, Jennis M, Lang W, Kuo GH, Gaul MD, Lenhard J, Demarest K, Ajami NJ, Liang Y, Hornby PJ. Du F, et al. J Pharmacol Exp Ther. 2018 Jun;365(3):676-687. doi: 10.1124/jpet.118.248575. Epub 2018 Apr 19. J Pharmacol Exp Ther. 2018. PMID: 29674332
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y. Nagata T, et al. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. doi: 10.1152/ajpendo.00545.2012. Epub 2012 Dec 18. Am J Physiol Endocrinol Metab. 2013. PMID: 23249697 Free article.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T, Sokolov V, Chu L, Tang W, Greasley PJ, Peilot Sjögren H, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Yakovleva T, et al. Diabetes Obes Metab. 2019 Dec;21(12):2684-2693. doi: 10.1111/dom.13858. Epub 2019 Sep 9. Diabetes Obes Metab. 2019. PMID: 31423699
224 results